Moderna sticks to long-term strategy in first-quarter update, ends pact with Metagenomi

Mod­er­na’s shift to a more “re­strained” pos­ture was on full dis­play Thurs­day morn­ing dur­ing its first-quar­ter earn­ings up­date.

CEO Stéphane Ban­cel and his team stayed away from mak­ing bold promis­es like they did in the past, as the com­pa­ny con­tin­ued to em­pha­size a re­turn to growth by 2026. De­spite be­ing pelt­ed by an­a­lysts’ ques­tions about the fu­ture of its vac­cines — RSV, with a PDU­FA date of May 12, was a par­tic­u­lar fo­cus — ex­ecs shared few de­tails be­yond what they’ve dis­closed at oth­er events this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.